Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2259 - Comparative and multimodal analysis of the EGFR, HER2, c-MYC, and MET copy number alteration using in situ hybridization in Korean colorectal cancer patients with integration of array-based copy number data from The Cancer Genome Atlas

Date

09 Sep 2017

Session

Poster display session

Topics

Translational Research;  Colon and Rectal Cancer

Presenters

Yoonjin Kwak

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

Y. Kwak1, S. Yun2, S.K. Nam1, A.N. Seo3, K.S. Lee1, H. Oh4, D.W. Kim4, S.B. Kang4, W.H. Kim5, H.S. Lee1

Author affiliations

  • 1 Department Of Pathology, Seoul National University Bundang Hospital, 13620 - Sungnamsi/KR
  • 2 Department Of Pathology, Samkwang Medical Laboratories, Seoul/KR
  • 3 Department Of Pathology, Kyungpook National University Hospital, Daegu/KR
  • 4 Department Of Surgery, Seoul National University Bundang Hospital, 13620 - Sungnamsi/KR
  • 5 Department Of Pathology, Seoul National University College of Medicine, Seoul/KR
More

Resources

Abstract 2259

Background

The purpose of this study was to explore gene copy number (GCN) variation of EGFR, HER2, c-MYC, and MET in patients with primary colorectal cancer (CRC).

Methods

Dual-colour silver-enhanced in situ hybridization was performed in tissue samples of 334 primary CRC patients. The amplification status (GCN ratio ≥2) and GCN gain (average GCN ≥4) data for the EGFR, HER2, c-MYC and MET genes were obtained. GCN variation was also assessed by the criterion of the 2013 ASCO/CAP guidelines for HER2 testing. The publicly available genetic data of 257 CRC cases from The Cancer Genome Atlas (TCGA) were used for comparative analysis.

Results

Amplification of EGFR, HER2, c-MYC and MET was detected in 8 (2.4%), 20 (6.0%), 29 (8.7%), and 14 (4.2%) patients, respectively. Of 66 patients with at least one amplified gene (HER2-MET co-amplification: two patients; HER2-c-MYC co-amplification: two patients; EGFR-c-MYC co-amplification: one patient). There were 109 patients with GCN gains of one or more genes (EGFR: 11/334, HER2: 29/334, c-MYC; 60/334, MET: 48/334) and 32.1% (35/109) had multiple GCN gains. When each GCN was assessed by the criterion of the ASCO/CAP 2013 guideline for HER2 testing, 116 people showed positive or equivocal results for one or more genes. The cumulative amplification status had no association with patients’ outcome. However, the cumulative results of the GCN gain and GCN status determined according to the ASCO/CAP guideline had a significant prognostic correlation in the univariate (P values of 0.006 and 0.022, respectively) and multivariate analysis (P values of 0.010 and 0.017, respectively). In analysis of TCGA data, high-level amplification of EGFR, HER2, c-MYC, and MET was observed in 1 (0.4%), 8 (3.1%), 11 (4.3%) and 1 (0.4%) cases, respectively. Copy number alteration status had no prognostic association in TCGA cohort.

Conclusions

In this study, we evaluated GCN variation of four genes in a large sample of Korean CRC patients. The amplification status was not related to patient outcome. However, the GCN gain and GCN status according to the ASCO/CAP 2013 guideline were independent prognostic factors.

Clinical trial identification

Legal entity responsible for the study

Individual

Funding

Korea Health Industry Development Institute (KHIDI)(grant number: HI14C1813)

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.